Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000409067 | SCV000485617 | likely pathogenic | Autosomal recessive polycystic kidney disease | 2016-01-15 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000409067 | SCV001202768 | likely pathogenic | Autosomal recessive polycystic kidney disease | 2023-07-19 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 370333). This variant has not been reported in the literature in individuals affected with PKHD1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change affects an acceptor splice site in intron 35 of the PKHD1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PKHD1 are known to be pathogenic (PMID: 19940839). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Baylor Genetics | RCV001332899 | SCV001525341 | pathogenic | Polycystic kidney disease 4 | 2020-09-27 | criteria provided, single submitter | clinical testing | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. |
Natera, |
RCV000409067 | SCV002078069 | likely pathogenic | Autosomal recessive polycystic kidney disease | 2020-12-09 | no assertion criteria provided | clinical testing |